COMMON STOCK PURCHASE WARRANT AYTU BIOSCIENCE, INC.Security Agreement • February 7th, 2019 • Aytu Bioscience, Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 7th, 2019 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●], 2019 (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Aytu BioScience, Inc., a Delaware corporation (the “Company”), up to [●]1 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WAIVER OF BLOCKERWaiver of Blocker • February 7th, 2019 • Aytu Bioscience, Inc • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 7th, 2019 Company Industry JurisdictionThis WAIVER OF BLOCKER (this “Waiver”) is entered into effective as of February 5, 2019 (the “Effective Date”) between Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (“Armistice”), and Aytu BioScience, Inc., a Delaware corporation (“Aytu”).
LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENTLicense, Development, Manufacturing and Supply Agreement • February 7th, 2019 • Aytu Bioscience, Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 7th, 2019 Company Industry JurisdictionTHIS LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”), dated as of November 2, 2018 (the “Effective Date”), by and between TRIS Pharma, Inc., a New Jersey corporation, with corporate offices at 2033 Route 130, Suite D, Monmouth Junction, New Jersey 08852 (“TRIS”), and AYTU BioScience, Inc., a Delaware corporation, with its principal offices at 373 Inverness Parkway, Suite 206, Englewood, CO (“AYTU”). (AYTU and TRIS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”).
EXCHANGE AGREEMENTExchange Agreement • February 7th, 2019 • Aytu Bioscience, Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 7th, 2019 Company Industry JurisdictionTHIS EXCHANGE AGREEMENT (this “Agreement”) is dated as of February 5, 2019, by and between Aytu BioScience, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the “Holder”).